Biovest International, Inc. (BVTI.PK)
Oncology Corporate Profile
- Products & Overview
- Recent News
HQ Location
324 S. Hyde Park Ave., Suite 350Tampa, FL 33606
Company Description
Biovest International develops personalized immunotherapies for life threatening cancers of the blood system. Biovest is the holder of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute for the commercialization of BiovaxID, a personalized biologic therapeutic cancer vaccine for the treatment of non-Hodgkin’s lymphoma. This therapy, referred to as BiovaxID, is currently in a phase 3 pivotal trial at 24 major medical institutions in the US.
Website: http://www.biovest.com/
Commercial Products
This company does not have any commercial productsPipeline Products
- Brand
- Generic
- Investigational
| Brand / Product | Class | Area of Study | Phase | Partnership |
|---|---|---|---|---|
| BiovaxID™ | immunotherapy | Follicular Non-Hodgkin's Lymphoma (f-NHL) | III | |
| BiovaxID™ | immunotherapy | Mantle Cell Lymphoma (MCL) | II |
View additional information on product candidates here »
Recent News Headlines
[Business Wire] - TAMPA, Fla. & MINNEAPOLIS----Biovest International, Inc. , a biotechnology company advancing its personalized cancer vaccine targeting non-Hodgkin’s lymphoma, today announced that the Company has retained the investment banking firm, ROTH Capital Partners, LLC .
[Business Wire] - TAMPA, Fla. & MINNEAPOLIS----Biovest International, Inc. today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to BiovaxID®, Biovest’s personalized cancer vaccine, for a second lymphoma indication: mantle cell lymphoma.
(St. Louis Business Journal) July 26, 2010 - The U.S. Food and Drug Administration has granted orphan drug designation to BiovaxID for the treatment of mantle cell lymphoma.
[Business Wire] - TAMPA, Fla. & MINNEAPOLIS----Biovest International, Inc. , a biotechnology company advancing its personalized cancer vaccine targeting non-Hodgkin’s lymphoma, today announced that the Company’s publicly-traded shares are now being quoted on the newly launched OTCQB™ Market.
[Business Wire] - TAMPA, Fla. & MINNEAPOLIS----Biovest International, Inc. today announced the appointment of Mr. Edmund C. King as an independent member of the Company’s Board of Directors. Mr. King’s qualifications and experience deem him to be a “financial expert” as defined by SEC rules under the Sarbanes-Oxley Act .
[Business Wire] - TAMPA, Fla. & MINNEAPOLIS----Biovest International, Inc. today announced at the Active Immunotherapeutics Forum in Barcelona, Spain, that the Company is targeting mantle cell lymphoma, in addition to follicular lymphoma, as a next indication for its personalized cancer vaccine, BiovaxID®.
(MarketWatch) June 22, 2010 - Biovest International, Inc. today announced at the Active Immunotherapeutics Forum in Barcelona, Spain, that the Company is targeting mantle cell lymphoma, in addition to follicular lymphoma, as a next indication for its personalized cancer vaccine, BiovaxID(R).
(MarketWatch) June 22, 2010 - Biovest International, Inc. today announced at the Active Immunotherapeutics Forum in Barcelona, Spain, that the Company is targeting mantle cell lymphoma, in addition to follicular lymphoma, as a next indication for its personalized cancer vaccine, BiovaxID(R).
[Business Wire] - TAMPA, Fla. & MINNEAPOLIS, Minn.----Biovest International, Inc. today announced that the Company will present the ongoing commercial development of the Company’s personalized cancer vaccine, BiovaxID®, on June 22nd at the Active Immunotherapeutics Forum 2010 in Barcelona, Spain.
[Business Wire] - TAMPA, Fla.----Accentia Biopharmaceuticals, Inc. today announced that the Company filed its proposed Plan of Reorganization with the U.S. Bankruptcy Court for the Middle District of Florida, Tampa Division.
TAMPA, Fla. & MINNEAPOLIS----Biovest International, Inc. today announced that it is under contract with the U.S. Department of Defense to supply AutovaxID™ bioreactors for the development and application of this platform technology for cell-culture-based vaccine production.